Indications |
Intravenous Susceptible infections Adult: 0.5-1 g every 8 hr. Child: Neonate: <7 days: 20 mg/kg 12 hrly (severe infection 40 mg/kg 12 hrly); 7-28 days: 20 mg/kg 8 hrly (severe infection 40 mg/kg 8 hrly). 1-3 mth: 10 mg/kg 8 hrly; >3 mth and <50 kg: 10-20 mg/kg 8 hrly. Renal impairment: Haemodialysis: Usual dose after dialysis session.
Intravenous Meningitis Adult: 2 g every 8 hr. Child: >3 mth and <50 kg: 40 mg/kg every 8 hr. Renal impairment: Haemodialysis: Usual dose after dialysis session.
Intravenous Cystic fibrosis Adult: Up to 2 g every 8 hr. Child: 4-18 yr: 25-40 mg/kg every 8 hr. Renal impairment: Haemodialysis: Usual dose after dialysis session.
Intravenous Skin and skin structure infections Adult: 500 mg every 8 hr. Child: ≥3 mth: <50 kg: 10 mg/kg (max: 500 mg) every 8 hr; >50 kg: 500 mg every 8 hr. Renal impairment: Haemodialysis: Usual dose after dialysis session.
Intravenous Intra-abdominal infections Adult: 1 g every 8 hr. Child: ≥3 mth: <50 kg: 20 mg/kg (max: 1 g) every 8 hr; >50 kg: 1 g every 8 hr. Renal impairment: Haemodialysis: Usual dose after dialysis session.
Intravenous Diabetic foot infection Adult: 1 g every 8 hr. Child: ≥3 mth: <50 kg: 20 mg/kg (max: 1 g) every 8 hr; >50 kg: 1 g every 8 hr. Renal impairment: Haemodialysis: Usual dose after dialysis session.
Special Populations: Renal impairment: CrCl: 26-50 mL/min: Usual dose every 12 hrs; 10-25 mL/min: ½the usual dose every 12 hrs; <10 mL/min: ½ the usual dose every 24 hrs. Reconstitution: Direct inj or infusion: add 10 ml of sterile water to 500 mg or 20 ml of sterile water to 1 g. Can be further diluted with compatible IV solution (50-200 ml). Incompatibility: Admixture: Amphotericin B, metronidazole and multivitamins. Y-site: Amphotericin B, diazepam and metronidazole. Syringe: Pantoprazole. |
||||||||||||||||||||||||||||||||||||||||||||||||
Contraindications |
Hypersensitivity. | ||||||||||||||||||||||||||||||||||||||||||||||||
Warnings / Precautions |
History of hypersensitivity to carbapenem, pencillins or other β-lactam antibiotics; infants <3 mth; renal insufficiency; neurological disorders; pregnancy, lactation. Not recommended for use in MRSA. | ||||||||||||||||||||||||||||||||||||||||||||||||
Adverse Reactions |
Diarrhoea, nausea, vomiting, abdominal pain; headache; constipation; rash, pruritus, uticaria; apnoea; phlebitis, thrombophlebitis, swelling and pain at inj site; disturbances in LFTs (may cause increases in serum transaminases, alkaline phosphatase, lactic dehydrogenase). Rarely: erythema multiforme; eosinophilia, thrombocytopenia, leucopenia, neutropenia; seizures and CNS effects reported in patients with underlying CNS disorders or renal impairment. Potentially Fatal: Anaphylaxis; pseudomembranous colitis; Stevens-Johnsons sydrome. |
||||||||||||||||||||||||||||||||||||||||||||||||
Overdose Reactions |
Treatment: symptomatic. In normal patients, rapid renal elimination will occur. In patients with renal impairment, haemodialysis will remove meropenem and metabolite. | ||||||||||||||||||||||||||||||||||||||||||||||||
Drug Interactions |
Serum levels may be increased by probenecid. May reduce serum valproic acid levels; sub-therapeutic levels may be reached in some patients. See Below for More meropenem Drug Interactions |
||||||||||||||||||||||||||||||||||||||||||||||||
Mechanism of Actions |
Meropenem is a carbapenem that works by inhibiting the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls by binding to one or more of the penicillin-binding proteins (PBPs), thus inhibiting cell wall biosynthesis resulting to bacterial lysis. Distribution: Widely distributed into body tissues and fluids; CSF; bile. Metabolism: More stable to renal dehydropeptidases; converted to one inactive metabolite. Excretion: Via urine within 12 hr by glomerular filtration and tubular secretion (70% unchanged). Elimination half-life: 1 hr. Removed by dialysis. |
||||||||||||||||||||||||||||||||||||||||||||||||
Storage Conditions |
Intravenous: Once reconstituted, up to 2 hr at 15-25°C or up to 12 hr at 4°C. | ||||||||||||||||||||||||||||||||||||||||||||||||
ATC Classification |
J01DH02 - meropenem ; Belongs to the class of carbapenems. Used in the systemic treatment of infections. | ||||||||||||||||||||||||||||||||||||||||||||||||
Storage |
Intravenous: Once reconstituted, up to 2 hr at 15-25°C or up to 12 hr at 4°C. | ||||||||||||||||||||||||||||||||||||||||||||||||
Available As |
|
Meropenem
Post Review about Meropenem Click here to cancel reply.
Meropenem Containing Brands
Meropenem is used in following diseases
Drug - Drug Interactions of Meropenem
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.